Key facts
- Canal Biosciences’s last known valuation is $14.5M (Apr 2026).
- It has raised $2.3M across 1 recorded rounds; the latest was Seed Round ($2.3M) in Mar 2026.
- Canal Biosciences has filed 1 Form D with the SEC, most recently Apr 2026 ($2.3M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Canal Biosciences
Funding rounds
1 roundsAbout Canal Biosciences
Developer of DNA sequencing library preparation technologies designed to preserve DNA template integrity. The company uses enzymes and adaptors in a dual-ligation workflow that attaches sequencing adaptors directly to native termini without end repair or A-tailing, safeguarding DNA molecules and increasing genomic data accuracy and efficiency, enabling researchers and clinical laboratories to retain true biological signals and power high-precision genomic applications.
- Sector
- Healthcare
- HQ
- Lowell, MA, United States
- Founded
- 2024
- Employees
- 6
- Website
- canalbiosciences.com/
- Ownership
- Privately Held (backing)
Canal Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Canal Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Canal Biosciences in its N-PORT filings yet. We sweep new filings monthly.